Alnylam to Webcast Conference Call to Discuss Phase II GEMINI Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection

Alnylam to Webcast Conference Call to Discuss Phase II GEMINI Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection CAMBRIDGE, Mass., Feb 25, 2008 (BUSINESS WIRE) -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will host a conference call to discuss the full results from the Phase II GEMINI study of ALN-RSV01, being presented at the International Symposium on Respiratory Viral Infections in Singapore. The webcast will take place on Friday, February 29, 2008 at 8:30 a.m. ET. To access the call, please dial 888-396-2384 (domestic) or 617-847-8711 (international) five minutes prior to the start time and provide the passcode 86570853. A replay of the call will be available from 10:30 a.m. ET on February 29, 2008 until March 7, 2008. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international), and provide the passcode 79263826. A live audio webcast of the call will also be available on the "Investors" section of the company's website, www.alnylam.com. An archived webcast will be available on the Alnylam website approximately two hours after the event and will be archived for 14 days. About Alnylam Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is leading the translation of RNAi as a new class of innovative medicines with peer-reviewed research efforts published in the world's top scientific journals including Nature, Nature Medicine, and Cell. The company is leveraging these capabilities to build a broad pipeline of RNAi therapeutics; its most advanced program is in Phase II human clinical trials for the treatment of respiratory syncytial virus (RSV) infection. In addition, the company is developing RNAi therapeutics for the treatment of a wide range of disease areas, including hypercholesterolemia, liver cancers, and Huntington's disease. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Medtronic, Novartis, Biogen Idec, and Roche. To reflect its outlook for key scientific, clinical, and business initiatives, Alnylam has established "RNAi 2010" which includes the company's plan to significantly expand the scope of delivery solutions for RNAi therapeutics, have four or more programs in clinical development, and to form four or more new major business collaborations, all by the end of 2010. Alnylam is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development, and commercialization of microRNA therapeutics. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, visit www.alnylam.com. SOURCE: Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. Investors Cynthia Clayton, 617-551-8207 or Media For Alnylam Pharmaceuticals, Inc. KMorrisPR Kathryn Morris, 845-635-9828 For Media Inquiries, please contact: [email protected] For Investor Inquiries, please contact: [email protected] MEDIA KIT Essential assets and documents related to Alnylam VIEW ALL PRESS RELEASES FOLLOW US Visit our social channels to learn more about the innovative work we are doing at Alnylam. Our Company Our Science Our Products Our News Investors Medical Professionals Patients Job Seekers Clinical Trials Corporate Responsibility Diversity, Equity & Inclusion Press Releases Capella Medical Resources (RNAi Science) Contact Us Sign Up For Updates Privacy Policy Media Kit Legal Notice Site Map Sign Up For Updates Copyright © Alnylam Pharmaceuticals, Inc. — All Rights Reserved

The release as fetched from its publisher. alnylam.com ↗